A small French biotech is trumpeting results from a trial suggesting its developmental drug could be used as part of an HIV cure. The phase 2a trial of AbiVax’s ABX464 pill is small but confirms ...

It’s vital people remember that HIV doesn’t give a damn if you’re gay, bi, straight – it can affect literally anyone. In fact ...

the study found. These “kicked” cells can then be targeted (“killed”) by immunotherapies to fully clear the insidious virus from the body. By pursuing this “kick and kill” strategy with EBC-46, ...

Their study, published in Health Care Management Science, found that a hypothetical 100% effective intervention addressing barriers to HIV treatment and care from depression, homelessness ...

Patients with HIV and hepatitis B coinfection are at an increased risk for hepatitis D, which is associated with an increased risk of liver-related complications and mortality, researchers found.

Some groups that receive funding as part of the program — which helps extend HIV treatment to some 20 million people globally, including more than 550,000 children — are halting the ...

today announced the opening of the ACACIA study (Antiretrovirals Combined with Antibodies for HIV-1 Cure in Africa), also known as A5417. ACACIA is a phase 2, double-blind, randomized study evaluating ...